Aaron Huang

Dr. Aaron Huang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2022 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
LKLakshay Khosla
Lakshay Khosla
AHAaron Huang
Aaron Huang
NKNikhil Kasarla
Nikhil Kasarla
TMThomas Monaghan
Thomas Monaghan
JWJeffrey P. Weiss
Jeffrey P. Weiss
AKAbdo E. Kabarriti
Abdo E. Kabarriti

Verified
Journal Article
Open access
PDF file
AHAaron Huang
Aaron Huang
GSGaurav Sharma
Gaurav Sharma
RPRohan Parikh
Rohan Parikh
ZJZhaosheng (Jims) Jin
Zhaosheng (Jims) Jin
FDFRANK S. DARRAS
FRANK S. DARRAS
SBSergio D. Bergese
Sergio D. Bergese
End-stage renal disease (ESRD) is a serious and lethal disease that carries with it a high morbidity and mortality rate if left untreated. Treating ESRD is conducted via renal replacement therapy and/or kidney transplantation, with the latter being the preferred option given the better outcomes and quality of life for the patients. However, as ESRD rises in prevalence, kidney transplantation rates remain largely unchanged. In every kidney transplantation, ischemia–reperfusion injury (IRI) is inevitable and the effect this has on the kidney depends based on donor type. IRI works through a variety of molecular mechanisms, primarily mitochondrial oxidative stress and programmed cell death mechanisms. Given the urgency to ensure the best outcomes for these limited kidney transplants, there has been a continued effort to find various potential therapeutic mechanisms to counteract IRI preoperatively, intraoperatively, and postoperatively. These include hypothermic machine perfusion, ischemic conditioning, nanoparticle removal of free radicals, peptide-based therapies, microRNA, and more. There is an ongoing effort to find the best way to mitigate IRI in kidney transplantation and this is being achieved through a better understanding of the molecular mechanisms of IRI.

23 June 2022 in The Prostate
Verified
Journal Article
Closed access
JHJohn R. Heard
John R. Heard
AHAaron Huang
Aaron Huang
LWLaura Werle
Laura Werle
KAKerry Adler
Kerry Adler
GBGeoffrey Bryant
Geoffrey Bryant
AWAndrew G. Winer
Andrew G. Winer

17 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
AHAaron Huang
Aaron Huang
WWWayne C. Waltzer
Wayne C. Waltzer
MHMichael Hung
Michael Hung
FDFRANK S. DARRAS
FRANK S. DARRAS
AKAdam Michael Kressel
Adam Michael Kressel
VRVictor Romanov
Victor Romanov
Background and Objectives: Bladder cancer (BCa) is characterized by high rates of recurrence and progression, underscoring the need for reliable non-invasive biomarkers. Circular RNAs (circRNAs) are covalently closed non-coding RNAs generated by back-splicing and are stable in biological fluids, including urine. Increasing evidence implicates circRNAs in BCa pathogenesis. However, identification of clinically relevant circRNAs remains challenging. This study aimed to streamline circRNA selection and identification of functional urinary circRNAs for potential use as biomarkers for BCa monitoring. Methods: Using a database-screening approach, we identified circRNAs with high predicted affinity (TDMD score > 1.1) to miR-101-3p (a tumor-suppressive microRNA in BCa). In addition, candidate circRNAs were prioritized based on the following: (i) derivation from genes involved in BCa tumorigenesis; and (ii) origination from exonic or long non-coding RNA sequences. The potential contribution of Argonaute-2 (Ago2) binding sites to circRNA activity or potential usage as biomarker was also evaluated. Expression levels were assessed in urine samples and BCa cell lines, and functional relevance was examined using molecular and cellular assays. Results: circCIAO1(5) and circMALAT1 fulfilled prioritization criteria and exhibited distinct Ago2-binding site profiles. Both circRNAs were upregulated in urine from BCa patients and in aggressive BCa cell lines and showed differential expression between remission and recurrent disease. CircCIAO1(5) demonstrated higher-affinity binding to miR-101-3p, while both circRNAs interacted with miR-101-3p and Ago2. Functional assays revealed enhanced proliferation, motility, and invasion upon circRNA overexpression, consistent with miR-101-3p sequestration and reduction in depression of its target oncogene—EZH2. Conclusions: circCIAO1(5) and circMALAT1 are promising candidates as urinary biomarkers for noninvasive BCa monitoring, illustrating the value of bioinformatics-guided determination of circRNA as potential biomarkers and significance of circRNA-mediated regulatory mechanisms in BCa biology.

6 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AHAaron Huang
Aaron Huang
WWWayne C. Waltzer
Wayne C. Waltzer
MHMichael Hung
Michael Hung
FDFRANK S. DARRAS
FRANK S. DARRAS
AKAdam Michael Kressel
Adam Michael Kressel
VRVictor Romanov
Victor Romanov
Background and Objectives: Bladder cancer (BCa) is characterized by high rates of re-currence and progression, underscoring the need for reliable non-invasive biomarkers. Circular RNAs (circRNAs) are covalently closed non-coding RNAs generated by back-splicing and are stable in biological fluids, including urine. Increasing evidence im-plies circRNAs in BCa pathogenesis; however, identification of clinically relevant circRNAs remains labor-intensive. This study aimed to streamline circRNA selection and identify functionally relevant urinary circRNAs in BCa. Methods: Using a database-screening ap-proach, we identified circRNAs with high predicted affinity to miR-101-3p, a tu-mor-suppressive microRNA in BCa. Candidate circRNAs were prioritized based on: (i) strong miR-101-3p binding potential; (ii) derivation from genes involved in BCa tumor-igenesis; and (iii) origination from exonic or long non-coding RNA sequences. The po-tential contribution of Argonaute-2 (Ago2) binding sites to circRNA–miRNA complex sta-bility was also evaluated. Expression levels were assessed in urine samples and BCa cell lines, and functional relevance was examined using molecular and cellular assays. Results: circCIAO1(5) and circMALAT1 fulfilled all prioritization criteria and exhibited distinct Ago2-binding site profiles. Both circRNAs were upregulated in urine from BCa patients and in aggressive BCa cell lines and showed differential expression between remission and recurrent disease. CircCIAO1(5) demonstrated higher-affinity binding to miR-101-3p, while RNA immunoprecipitation confirmed interactions of both circRNAs with miR-101-3p and Ago2. Functional assays revealed enhanced proliferation, motility, and invasion upon circRNA expression, consistent with miR-101-3p sequestration and derepression of miR-101-3p target oncogene-EZH2. Conclusions: circCIAO1(5) and circMALAT1 represent promising urinary biomarkers for BCa, illustrating the value of bioinformatics-guided circRNA discovery and significance of circRNA-mediated regulatory mechanisms in BCa biology.

6 December 2023 in Continence
Verified
Journal Article
Open access
LKLakshay Khosla
Lakshay Khosla
AHAaron Huang
Aaron Huang
SGSusan Gong
Susan Gong
DBDonald L. Bliwise
Donald L. Bliwise
JLJason M. Lazar
Jason M. Lazar
AKAbdo E. Kabarriti
Abdo E. Kabarriti